Search

everythinglearnresearchcommunity

for

Search:↓

Taking oral isotretinoin with creams worked better for treating a type of hair loss than creams alone.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

Baricitinib is an effective treatment for severe alopecia areata.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Baricitinib shows promise for treating alopecia areata with mild side effects.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Upadacitinib may effectively treat resistant lichen planopilaris.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.

Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.

Baricitinib effectively treats certain skin conditions but may have serious side effects.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.